Downregulation of lncRNA CCDC26 contributes to imatinib resistance in human gastrointestinal stromal tumors through IGF-1R upregulation
Imatinib is the first line of therapy for patients with metastatic or gastrointestinal stromal tumors (GIST). However, drug resistance limits the long-term effect of imatinib. Long non-coding RNAs (lncRNAs) are emerging as key players in regulating drug resistance in cancer. In this study, we invest...
Main Authors: | Jingyi Yan, Didi Chen, Xiaolei Chen, Xuecheng Sun, Qiantong Dong, Changyuan Hu, Feng Zhou, Wei Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
|
Series: | Brazilian Journal of Medical and Biological Research |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2019000600610&lng=en&tlng=en |
Similar Items
-
Crossing-over to imatinib 800 mg in a patient with GIST, after progression with standard
dosage: a case report
by: Giuseppe Naso, et al.
Published: (2015-10-01) -
Imatinib as adjuvant therapy for high risk GIST: a case report
by: Patrizia Lista, et al.
Published: (2015-10-01) -
Imatinib dose optimisation following the disease progression in a patient with metastatic GIST
by: Mariangela Parodi, et al.
Published: (2015-10-01) -
Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour
by: Michael C. Onyema, et al.
Published: (2020-07-01) -
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
by: Seidel Christoph, et al.
Published: (2012-05-01)